SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02419287
Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene
The purpose of this study is to determine the response and the duration of it in patients
affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment
that will be treated with crizotinib.
Name: crizotinib
Type: Drug
Group Labels: 1 crizotinib
Primary Outcomes
Measure: objective response rates (ORR) in subjects with ALK+ lymphomas resistant or refractory to standard cytotoxic treatment, according to RECIST 1.1 criteria. Time: the entire duration of the study (5 years)
Measure: Duration ORR Time: the entire duration of the study (5 years)
Secondary Outcomes
Measure: Progression free survival (PFS) in ALK+ lymphoma patients treated with crizotinib, that are resistant or refractory to standard cytotoxic treatment. Time: the entire duration of the study (5 years)
Measure: Number of patients with adverse events after crizotinib treatment Time: the entire duration of the study (5 years)
Measure: Quality of Life (QoL) in this population of patients using the the EORTC - C30 Quality of Life questionnaire Time: the entire duration of the study (5 years)
Measure: Overall survival (OS) in ALK+ lymphoma patients treated with crizotinib Time: the entire duration of the study (5 years)
Purpose: Treatment
Allocation: N/A
Single Group Assignment
There is one SNP
SNPs
1 I1171N
Although crizotinib shows activity, relapses occur typically within 5 months after starting
treatment and were supported by mutations like I1171N. --- I1171N ---